PT  - JOURNAL ARTICLE
AU  - Jiaqi Wang
AU  - Yu Lushan
AU  - Huidi Jiang
AU  - Xiaoli Zheng
AU  - Su Zeng
TI  - Epigenetic regulation of differentially expressed Drug-metabolizing enzymes in cancer
AID  - 10.1124/dmd.120.000008
DP  - 2020 Jan 01
TA  - Drug Metabolism and Disposition
PG  - DMD-MR-2020-000008
4099  - http://dmd.aspetjournals.org/content/early/2020/06/29/dmd.120.000008.short
4100  - http://dmd.aspetjournals.org/content/early/2020/06/29/dmd.120.000008.full
AB  - Drug metabolism is a biotransformation process of drugs, catalyzed by drug-metabolizing enzymes (DMEs) including phase I DMEs and phase II DMEs. The aberrant expression of DMEs occurs in the different stages of cancer. It can contribute to the development of cancer and lead to individual variations in drug response by affecting the metabolic process of carcinogen and anticancer drugs. Apart from genetic polymorphisms, the one we know the most about, current evidence indicates that epigenetic regulation is also central to the expression of DMEs. This review summarizes differentially expressed DMEs in cancer and related epigenetic changes, including DNA methylation, histone modification, and non-coding RNAs (ncRNAs). Exploring the epigenetic regulation of differentially expressed DMEs can provide a basis for implementing individualized and rationalized medication. Meanwhile, it can promote the development of new biomarkers and targets for the diagnosis, treatment, and prognosis of cancer.